Cons indications
- History of hypersensitivity to Femara or any of the excipients (see section composition).
- Known hypersensitivity to sulfonamides.
- Peptic ulcer or gastrointestinal bleeding (GI).

- History of asthma, acute rhinitis, nasal polyps, angioedema, urticaria or other allergic-type reactions triggered by taking acetylsalicylic acid or NSAIDs including COX- 2 (cyclo-oxygenase-2).
- Severe hepatic impairment (serum albumin <25 g / L or Child-Pugh score> = 10).
- Patients with estimated creatinine clearance <30 ml / min.
- Inflammatory bowel disease.
- Congestive heart failure (NYHA II-IV).
- Ischemic heart disease, peripheral arterial disease and / or history of stroke (including transient ischemic attack).
- Pregnancy and women of childbearing age, in the absence of effective contraception. In both species studied, celecoxib caused malformations. In humans, the risk during pregnancy is not known but can not be ruled out: there are no clinical data on pregnancies exposed to celecoxib. Studies in animals (rats and rabbits) showed toxicity to reproduction including malformations. In humans, the risk during pregnancy is unknown but can not be excluded. Like other drugs that inhibit prostaglandin synthesis, celecoxib may cause uterine inertia and premature closure of the ductus arteriosus during the last trimester of pregnancy. Celecoxib is cons-indicated during pregnancy and in women who may become pregnant. If a woman becomes pregnant during treatment, celecoxib should be discontinued.
- Breastfeeding: There are no studies on the excretion of celecoxib in human breast milk. Celecoxib is excreted in the milk of lactating rats at concentrations similar to those found in plasma. Women who take celecoxib should not breastfeed.
- The CELEBREX 100mg capsules contain lactose (149.7 mg). Due to the presence of lactose, this drug should be administered in case of congenital galactosemia, malabsorption of glucose and galactose or lactase deficiency.
- Children: Celecoxib is not indicated for children.